2021
Biochemical markers for severity and risk in GBA and LRRK2 Parkinson’s disease
Thaler A, Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Cedarbaum J, Orr-Urtreger A, Shenhar-Tsarfaty S, Mirelman A. Biochemical markers for severity and risk in GBA and LRRK2 Parkinson’s disease. Journal Of Neurology 2021, 268: 1517-1525. PMID: 33388928, DOI: 10.1007/s00415-020-10325-4.Peer-Reviewed Original ResearchConceptsNon-manifesting carriersProdromal Parkinson's diseaseWhite blood countParkinson's diseaseMicroalbumin/creatinine ratioNeutrophil/lymphocyte ratioGBA-PD patientsWorse motor performanceGlomerular filtration rateLRRK2 mutation carriersC-reactive proteinIdiopathic Parkinson's diseaseGBA-NMCGBA-PDLRRK2-NMCCreatinine ratioLRRK2-PDLymphocyte ratioVitamin DBlood countFiltration rateIdiopathic PDMutation carriersPD severityBiochemical markers
2009
Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease
Kas A, Bottlaender M, Gallezot JD, Vidailhet M, Villafane G, Grégoire MC, Coulon C, Valette H, Dollé F, Ribeiro MJ, Hantraye P, Remy P. Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease. Cerebrovascular And Brain Metabolism Reviews 2009, 29: 1601-1608. PMID: 19491921, DOI: 10.1038/jcbfm.2009.74.Peer-Reviewed Original ResearchConceptsParkinson's diseasePositron emission tomographyDistribution volumeDopaminergic functionPD severityCerebral nicotinic acetylcholine receptorsStriatal dopaminergic functionNicotinic acetylcholine receptorsNAChR densityNeuroprotective actionNigrostriatal systemClinical scoresPD patientsSubstantia nigraHealthy controlsPD groupPostmortem studiesLower incidenceNicotinic receptorsPET markersPET scansPD stagesAcetylcholine receptorsEmission tomographyDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply